Cancer News and Research

Latest Cancer News and Research

Omeros to develop new drugs for major diseases

The Life Sciences Discovery Fund (LSDF) today announced a $5 million grant to Seattle-based Omeros Corporation (NASDAQ: OMER) to discover, develop, and commercialize new drugs to treat a variety of major diseases. With successful generation of proceeds through partnering and the sales of drugs in the marketplace, an additional outcome of the grant would be establishment of a new non-profit initiative to advance the life sciences sector and improve health and economic growth in Washington state.

26 Oct 2010

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. Their research showed that the Notch pathway and Hes1 gene play a key role in promoting the metastasis of osteosarcoma, the most common form of bone cancer in children.

26 Oct 2010

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of renal cell carcinoma (RCC), the majority of surveyed European oncologists who favor Pfizer's Sutent indicate that they would switch to an emerging therapy only if it extended progression-free survival (PFS) by at least an additional two to three months, assuming the agent's safety and tolerability profile was comparable to that of Sutent.

26 Oct 2010

New source of blood-derived biomarkers may help in cancer diagnosis

The future of cancer diagnosis may lie in just a few milliliters of blood, according to a research team led by Professor Arie Admon of the Technion-Israel Institute of Technology.

26 Oct 2010

Study finds ABVD standard chemotherapy effective for Hodgkin's lymphoma

A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease, according to a first-of-its-kind randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

IDC grants MedImmune global rights to GLA adjuvant

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

26 Oct 2010

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Tengion, Inc. a leader in regenerative medicine, presented new data on Saturday, October 23, 2010 in a podium presentation at the American Society for Transplantation's Annual Scientific Exchange in Orlando, FL. The presentation highlighted new early data from Tengion's Neo-Kidney Augment development program demonstrating promising improvements in kidney function with an autologous cellular therapy approach to kidney regeneration in a canine model of chronic kidney disease.

26 Oct 2010

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Breast Cancer Awareness month spotlights the increasingly high incidence of breast cancer, and also brings attention to the question, "what is being done to speed and ease recovery?"

26 Oct 2010

Viral microRNA allows EBV to hide within cells and evade immune system

While most commonly associated with mononucleosis, Epstein-Barr virus (EBV) has been linked to many diseases that affect people long after the initial infection takes place, including some forms of cancer. In the current issue of the Journal of Biological Chemistry, scientists at The Wistar Institute describe how viral microRNA - small segments of RNA that suppress the effects of gene activity - allows EBV to hide within cells and evade the immune system.

26 Oct 2010

Cancer researcher to receive 2010 AACR Award of excellence

John D. Groopman, Ph.D., has been selected to receive the 2010 American Association for Cancer Research-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research

26 Oct 2010

Eye-gaze technology opens world of communication for Rett Syndrome children

Special eye-gaze technology now being used in the Department of Neurology at The Children's Hospital at Montefiore (CHAM) is revealing the hidden, inner world of children who have Rett Syndrome, a rare and severe autism spectrum disorder that primarily affects little girls. It is a neurological disease in which mobility and autonomic functions are severely impaired, seizures and orthopedic problems are common, and the children lose functional hand use and the ability to speak.

26 Oct 2010

Routine prostate cancer screening reduces metastasis risk

Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment, compared to men who were treated prior to the use of routine screening, according to the first study-of-its-kind presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

CINJ researcher receives Clinical/Basic Science Research Award

Amar Rewari, MD, MBA, a researcher from The Cancer Institute of New Jersey (CINJ), has been chosen to receive the Clinical Award in Clinical/Basic Science Research at the 52nd Annual Meeting of The American Society for Radiation Oncology (ASTRO) in San Diego next month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

26 Oct 2010

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.

26 Oct 2010

Short course of radiation before surgery reduces rectal cancer recurrence: Study

Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years, according to a large, randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

Genmab A/S announced today the start of a Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen to which they responded.

26 Oct 2010

La Jolla Institute scientist wins Malpighi Medal for pioneering work in heart disease

Klaus Ley, M.D, a scientist at the La Jolla Institute for Allergy & Immunology, was recently awarded the prestigious Malpighi Medal at the World Congress for Microcirculation in Paris, France. A lifetime achievement award presented by the European Society for Microcirculation, Dr. Ley received the honor in recognition of his pioneering endeavors in vascular immunology, a scientific discipline that he helped to pioneer, which looks at novel immune-based approaches to combating heart disease. He is only the 17th recipient of the biennial award worldwide.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

26 Oct 2010

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

The John Theurer Cancer Center at Hackensack University Medical Center unveiled a new $130-million, 155,000-square-foot comprehensive cancer facility that will enhance the cancer center's ability to deliver multidisciplinary extraordinary care, best-in-class clinical quality, and cutting-edge research. The doors will open for patients in January 2011.

26 Oct 2010

Cancer News and Research

Latest Cancer News and Research

Omeros to develop new drugs for major diseases

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

New source of blood-derived biomarkers may help in cancer diagnosis

Study finds ABVD standard chemotherapy effective for Hodgkin's lymphoma

IDC grants MedImmune global rights to GLA adjuvant

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Viral microRNA allows EBV to hide within cells and evade immune system

Cancer researcher to receive 2010 AACR Award of excellence

Eye-gaze technology opens world of communication for Rett Syndrome children

Routine prostate cancer screening reduces metastasis risk

CINJ researcher receives Clinical/Basic Science Research Award

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

Short course of radiation before surgery reduces rectal cancer recurrence: Study

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

La Jolla Institute scientist wins Malpighi Medal for pioneering work in heart disease

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in